Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02940353
Other study ID # T-188
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date June 2022

Study information

Verified date September 2022
Source Nobel Biocare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, single cohort, multi-center study evaluating the TREFOIL concept for the treatment of edentulous or patients with failing mandibular dentition over 5 years. 90 patients (15 per centre) will be included. The subject population is at least 18 years old, in need of an implant restored full prosthesis providing sufficient bone in the interforaminal where a fixed restoration on three implants is regarded as an appropriate treatment solution. The components are TREFOIL treatment concept (implants and framework).


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date June 2022
Est. primary completion date June 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Obtained informed consent from the subject. - The subject is at least 18 years of age (passed cessation of growth) and not older than 80 years. - The subject is in such a physical and mental condition that a 5-year follow-up period can be carried out without foreseeable problems. - The subject fulfills the prerequisite that a harmonic, stable occlusal relationship can be achieved with opposing natural teeth resp. fixed or removable opposing dentition (tooth or implant based) or soft tissue born denture. - The subject is willing and able to comply with all study related procedures (such as exercising oral hygiene and attending all follow-up procedures). - The subject is compliant with good oral hygiene. - The subject has an edentulous mandible or failing mandibular dentition providing sufficient bone in the interforaminal where a fixed restoration on three (3) implants is regarded as an appropriate treatment solution. - The subject has an osseous architecture enough to receive three implants with a length of at least 11.5 mm and a diameter of 5 mm in the interforaminal (e.g. jaw volume B, C or D; inter foramina distance at least 20 mm; buccal/lingual width at least 6-7 mm, vertical height after leveling bone sufficient to receive an implant of at least 11.5 mm length). - The subject has a jaw curvature that fits to the prefabricated framework design. - Implants will be placed in healed or extraction sites (clinical stability has to be ensured). - The implant sites are free from infection and extraction remnants. - The subjects as well as the implant sites fulfill the criteria for early loading. Smokers that have reduced their consumption may be included after a certain test phase (e.g. test phase for reduction from 2 to 1 packages of cigarettes should be at least 6 months). Class II inter-jaw relation patients are not an exclusion criteria per se. Based on the individual judgment of the clinician those patients may be treated. Subject inclusion criteria at time of surgery - After bone leveling sufficient mandible bone volume in the interforaminal present for three (3) implants with a length of at least 11.5 mm and a diameter of 5 mm. - After bone leveling the jaw curvature does fit to the prefabricated framework. - The implant sites are free from infection and extraction remnants. - The subject as well as the implant sites fulfill the criteria for early loading. Exclusion Criteria: - The subject is not able to give her/his informed consent of participating. - Health conditions, which do not permit the surgical (including anesthesia) or restorative procedure. - Reason to believe that the treatment might have a negative effect on the subject's overall situation (psychiatric problems), as noted in subject records or history. - Any disorders in the planned implant area such as previous tumors, chronic bone disease or previous irradiation. - Alcohol or drug abuse as noted in subject records or in subject history. - Smoking of more than 1 package of cigarettes per day (> 20 cigarettes or equivalent). - Uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of neglecting doctor's recommendations regarding treatment, food and alcohol intake or A1c level above 8%. - Bisphosphonate therapy - based on individual judgment of the clinician (if intravenously administered or too high oral doses recently before surgery and during follow-up period). - Pathologic occlusion, e.g. severe bruxism or other destructive habits. - Lack of opposing dentition or unstable occlusion. - Ongoing infections, endodontic or periodontal problems in opposing teeth or implants. - Subject shows an unacceptable oral hygiene. - Subject has allergic or adverse reactions to the restorative material.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TREFOIL concept


Locations

Country Name City State
Australia Branemark Centre Perth Western Australia
Chile Clinica Rosenberg Santiago Santiago De Chile
Italy University of Verona Verona
Spain Instituto Davó, Hospital Medimar Internacional Alicante
United States Dr. Higuchi &Skinner Spokane Washington

Sponsors (1)

Lead Sponsor Collaborator
Nobel Biocare

Countries where clinical trial is conducted

United States,  Australia,  Chile,  Italy,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative survival rates for the implants 5 years